Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child

BACKGROUND: Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yogarajah, J., Gouveia, C., Iype, J., Häfliger, S., Schaller, A., Nuoffer, J.M., Fux, M., Gautschi, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060064/
https://www.ncbi.nlm.nih.gov/pubmed/35664977
http://dx.doi.org/10.1002/ski2.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060064/
https://www.ncbi.nlm.nih.gov/pubmed/35664977
http://dx.doi.org/10.1002/ski2.25

Ejemplares similares